Proactive - Interviews for investors

BioHarvest Sciences CEO Ilan Sobel and Chairman Dr. Zaki Rakib joined Steve Darling from Proactive to share the company has announced its upcoming debut on the Nasdaq exchange, with trading scheduled to commence on November 12, under the symbol “BHST.” Currently listed on the OTCQB and Canadian Securities Exchange, BioHarvest will complete its OTCQB trading by the close of November 11 before making its transition to Nasdaq.

CEO Ilan Sobel and Chairman Dr. Zaki Rakib highlighted the importance of this listing in enhancing the company's profile and shareholder value. Dr. Rakib described the Nasdaq debut as a pivotal milestone for the company’s growth trajectory. BioHarvest Sciences specializes in botanical synthesis, utilizing a patented technology to produce active plant ingredients without cultivating the entire plant. This innovative approach positions BioHarvest to capture new market opportunities and provide consistent, sustainable solutions in the health and wellness sectors.

The move aims to increase visibility, attract institutional investors, and lay the groundwork for future growth.

#proactivinvestors #cse #bhsc #otcqb #cnvcf #pharma #biotech #hearthealth #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #FinancialResults, #MarketingEfficiency, #ProductLaunch, #CoffeeProducts, #TeaProducts, #BusinessGrowth, #InvestorInterest, #BusinessStrategy, #FinancialForecast, #MarketExpansion, #CorporateDevelopment, #ManagementFocus, #EarningsReport, #StockMarket, #InvestmentOpportunity, #CorporateNews

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Reconnaissance Energy Africa CEO Brian Reinsborough joined Steve Darling from Proactive to share news the company has made history as the first publicly traded oil and gas company to be listed on the Namibian Stock Exchange. The company emphasizing that the dual listing, under the symbol "REC," reflects the company’s significant footprint as the largest acreage holder among publicly traded oil and gas exploration companies operating onshore in Namibia. ReconAfrica's primary listing remains on the TSX-Venture Exchange, ensuring broad investor access.

In addition to its dual listing achievement, ReconAfrica received approval for the First Renewal Exploration Period for its onshore PEL 001 license in Botswana. Covering nearly 1.9 million acres, this license renewal, valid until 2028, mandates ReconAfrica to carry out extensive geotechnical evaluations, vegetation mapping, water studies, methane seep detection, environmental impact assessments, and contribute to Botswana's petroleum exploration and training initiatives.

Exploration activities are advancing at the Naingopo well, where drilling resumed in mid-October and has reached 3,500 meters. The company aims to reach a target depth of 3,800 meters, with results expected post-completion following thorough logging and analysis for oil or natural gas samples.

ReconAfrica is also preparing for Namibia's first onshore 3D seismic survey at its PEL 73 license. Scheduled for mid-2025, this 3D seismic acquisition will span 500 kilometers, enhancing the geological understanding of the Kavango Rift Basin and positioning the company to further explore this promising region.

#proactiveinvestors #reconnaissanceenergyafricaltd #tsxv #reco #otcqx #recaf

#NamibiaExploration #BrianReinsborough #OilAndGas #NamibiaStockExchange #EnergySector #3DSeismic #Namibia #Botswana #ProactiveInvestors #EnergyExploration

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Sprintex Ltd (ASX:SIX) managing director Jay Upton joins Proactive’s Tylah Tully to discuss the company’s latest update.

It has delivered five G15 Jet Blowers to Euroteck Environmental Pvt. Ltd in India for evaluation, aiming to enhance aeration technology within Euroteck's water treatment systems.

This evaluation project could lead to an exclusive supply agreement, with Euroteck testing the energy-efficient blowers in its wastewater treatment operations.

Results from the testing are anticipated in the coming weeks, potentially demonstrating significant efficiency improvements.

Sprintex’s collaboration with Euroteck aligns with its strategy to penetrate India’s industrial and municipal water treatment sectors.

Euroteck, a leader in wastewater solutions with more than 3,000 Aire-O2 Triton® systems in India, seeks to incorporate Sprintex’s high-efficiency blowers to enhance energy savings.

Sprintex’s G15 Jet Blowers have demonstrated up to 69% electricity savings in other applications, matching Euroteck's sustainability goals and supporting their AI-driven optimisation systems.

Upton highlighted Euroteck’s reach and commitment to sustainability.

#ProactiveInvestprs #Sprintex #ASX  #EuroteckIndia, #JetBlowers, #WaterTreatment, #WastewaterManagement, #EnergyEfficiency, #G15JetBlower, #IndiaIndustrial, #MunicipalWater, #SustainableSolutions, #AerationTechnology, #AIOptimization, #IntelHydroPlatform, #ElectricitySavings, #WastewaterSolutions, #EnvironmentalTechnology, #SustainableGrowth, #MarketExpansion, #WaterTreatmentInnovation, #BlowerTechnology

Green Technology Metals Ltd (ASX:GT1, OTC:GTMLF) managing director Cameron Henry joins Proactive’s Tylah Tully to discuss the 6,900-metre diamond drilling program the company has planned at its Junior Lithium Project in Ontario, Canada.

The project spans 10,856 hectares with a conceptual exploration target estimated between 4 and 9 million tonnes of lithium with grades of 1.0% to 1.5% Li₂O.

The two-phase drilling program will begin with a 3,450-metre phase, with further drilling depending on initial results.

The Despard prospect, a key focus within the Junior Project, has shown promise through recent fieldwork.

A 750-metre mineralised strike at Despard yielded rock chip assays with lithium oxide grades up to 5.06%, and revealed a lithium-cesium-tantalum (LCT) pegmatite zone extending 200 metres southwest of the Main Zone.

Historical drilling in the area indicated pegmatite layers over 19 metres thick.

This exploration effort aligns with Green Technology Metals' broader strategy to expand lithium resources at the Eastern Hub, potentially supplying its planned Seymour concentrator.

The company has committed to respecting Indigenous heritage and collaborating with local Indigenous groups to support cultural stewardship while advancing resource development.

#ProactiveInvestors #GreenTechnologyMetals #ASX #LithiumExploration, #OntarioLithium, #DiamondDrilling, #JuniorLithiumProject, #DespardProspect, #SpodumenePegmatite, #ResourceExpansion, #MiningNews, #SeymourConcentrator, #BatteryMaterials, #ElectricVehicleSupply, #CriticalMinerals, #MiningInvestments, #CanadaMining, #ExplorationProgramme, #LithiumIndustry, #SustainableMining, #IndigenousPartnerships, #MineralExploration

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Helix Resources Ltd (ASX:HLX).

The company has extended the mineral footprint of its Bijoux copper prospect in central New South Wales following recent RC drilling, which identified copper sulphide mineralisation over a 290-metre strike. Located nine kilometres south of Helix’s Canbelego resource, Bijoux is characterised as a CSA-style copper deposit and remains open for exploration at greater depths and along the current strike.

The latest drilling campaign, comprising eight RC holes, confirmed copper mineralisation in each hole, including a high-grade section of 2 metres at 2.92% copper within a broader interval of 26 metres grading 0.58% from 84 metres. This builds on previous high-grade results, such as 2 metres at 5.76% from 182 metres. Helix has scheduled further RC and diamond drilling to deepen the understanding of the deposit’s structure.

Bijoux forms part of the Rochford Copper Trend, a 30-kilometre mineral belt. Helix's approach combines geochemical sampling and drilling, with results demonstrating the potential for new discoveries within the Cobar Basin. Further exploration is planned at additional sites, including the Louis copper prospect and the Muriel Tank gold field, with ongoing work across Helix’s extensive tenements.

#ProactiveInvestors #HelixResources #ASX #JustTheFacts #CopperExploration, #BijouxProspect, #CSADeposit, #CobarBasin, #MiningUpdate, #CopperStrike, #RCDrilling, #MineralExploration, #NewSouthWalesMining, #RochfordTrend, #HighGradeCopper, #DiamondDrilling, #GeochemicalSampling, #MurielTankGold, #LouisProspect, #CopperAnomalies, #AustralianMining, #ExplorationSuccess, #CobarExploration

Percheron Therapeutics CEO James Garner joined Steve Darling from Proactive to discuss the company’s unique approach to treating Duchenne muscular dystrophy (DMD), a progressive genetic disorder primarily affecting boys and characterized by muscle degeneration. Current treatments, such as gene therapy and anti-inflammatory medications, often fall short in effectively managing the disease. Percheron’s lead candidate, ATL1102, or avicursen has demonstrated promising results in early pilot studies by helping stabilize disease progression in later-stage patients.

The company is now conducting an international Phase 2B trial to gather more robust data for regulatory review, with initial results anticipated in December 2024. Garner highlighted the urgent need for new and effective therapies for DMD, noting that avicursen's development could significantly improve patients' quality of life.

This approach could offer hope to DMD patients and their families, who often face limited treatment options.

#proactiveinvestors #percherontherapeuticslimited #asx #per #clinicaltrial #pharma #jamesgarner

#DuchenneMuscularDystrophy #ClinicalTrials #ATL1102 #JamesGarner #Biotech #GeneTherapy #MuscularDystrophy #HealthInnovations #OrphanDiseases#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Evion Group NL (ASX:EVG) managing director David Round joins Proactive’s Tylah Tully to discuss the company’s latest milestone.

It has announced initial sales of $2 million from its 50/50 joint venture (JV) expandable graphite operations near Pune, India.

Production testing and sample approvals are complete, allowing full production to begin.

The JV, Panthera Graphite Technology (PGT), expects to produce around 400 tonnes of expandable graphite over the next 10 weeks, with a contract in place to sell 386 tonnes to Technografit GmbH, a prominent European graphite trading company, at favourable terms.

The agreed price ranges between US$3,000 and US$3,300 per tonne, with production costs estimated at US$1,500–$1,750 per tonne, resulting in a robust operating margin.

The JV anticipates further contracts for expanded sales through 2025, driven by growing demand for expandable graphite in electric vehicle, aerospace, energy storage, and electronics sectors.

The plant has an annual capacity of 2,000 tonnes, with plans to increase to 4,000 tonnes, potentially adding an additional US$6 million in annual revenue.

The global demand for expandable graphite, fuelled by its use in fire retardants and energy storage, is forecasted to grow, with China’s market share expected to decrease, highlighting opportunities for Evion outside China.

Evion is also advancing its battery anode material plans in Madagascar, where it seeks additional permits and funding to support graphite production.

#Evion #ExpandableGraphite #GraphiteMarket #BatteryMaterials #ASX #ElectricVehicles #EnergyStorage #SustainableMining #PGTIndia #FireRetardant #GraphiteProduction #IndiaOperations #MineralSupply #TechnoGrafit #RenewableEnergy #LithiumIonBatteries #GlobalGraphite #JointVenture #MadagascarMining #FutureMaterials

Anthony Ginsberg, CEO of GinsGlobal Index Fund, discussed the performance and outlook of the GinsGlobal Tech Megatrend ETF with Proactive’s Steve Darling, highlighting the fund’s recent success and the potential for accelerated growth following Donald Trump’s re-election. Ginsberg expressed optimism for tech sector expansion, with Trump’s anticipated policy adjustments expected to relax antitrust regulations. "We’re optimistic about fewer restrictions on mergers and acquisitions for big tech companies, which could boost sector growth and investment," he shared.

Ginsberg pointed out that the ETF’s holdings in cloud computing and social media have already benefitted, noting recent earnings reports from industry giants Google and Microsoft, each posting cloud revenue increases exceeding 30%. With the Federal Reserve indicating possible interest rate cuts, he foresees a sustained tech rally into 2024.

Looking ahead, Ginsberg anticipates heightened M&A activity, especially in automation and robotics, as firms shift more manufacturing to the U.S., aligning with potential policy changes. He emphasized the ETF's commitment to equal-weighted indexing, which ensures balanced exposure across key subthemes like AI, blockchain, and cybersecurity, allowing investors to benefit from diverse growth areas within the tech megatrend landscape.

#TechMegatrendETF, #AnthonyGinsberg, #FourthIndustrialRevolution, #AI, #Cybersecurity, #CloudComputing, #SocialMedia, #FutureCars, #Robotics, #InterestRateCuts, #Diversification, #GlobalHoldings, #Nasdaq, #NIO, #BYD, #P/ERatios, #TechInvesting, #StockRebalancing, #MarketTrends#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Candel Therapeutics Chief Scientific Officer Dr. Francesca Barone joined Steve Darling from Proactive to share news the company is presenting at the Society for Immunotherapy of Cancer (SITC) conference. Barone, the company’s Chief Scientific Officer shared details on CAN-3110, a first-in-class oncolytic viral therapy designed to selectively replicate within cancer cells. CAN-3110 is engineered to minimize effects on healthy cells while triggering a potent immune response within tumors, a promising innovation for treating difficult cancers like recurrent high-grade glioma and resistant melanoma.

“Immunotherapy has transformed melanoma treatment, but many patients remain resistant,” Dr. Barone explained. Preclinical melanoma data shows CAN-3110 significantly reduces tumor burden while activating the immune system in cell models. The therapy’s success in melanoma trials also hints at broader applications, with Dr. Barone citing potential future investigations into triple-negative breast cancer and sarcoma.

With a strong safety profile, Candel Therapeutics is now considering targeted preclinical trials to assess CAN-3110’s impact across additional challenging cancers. This novel therapeutic could offer new hope for patients with limited options, potentially transforming treatment landscapes for resistant tumor types.

#proactiveinvestors #candeltherapeuticsinc #nasdaq #OncolyticVirus #Immunotherapy #CancerResearch #MelanomaTreatment #CAN3110 #FrancescaBarone #SITC #BiotechNews #CancerBreakthrough

#proactiveinvestors #candeltherapeuticsinc #nasdaq

#OncolyticVirus #Immunotherapy #CancerResearch #MelanomaTreatment #CAN3110 #FrancescaBarone #SITC #BiotechNews #CancerBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Argenica Therapeutics Ltd (ASX:AGN, OTC:OTCMKTS: AGNTF) CEO and managing director, Dr Liz Dallimore talked with Proactive's Stephen Gunnion about the company’s ongoing clinical trial of its lead drug candidate, ARG-007, targeting acute ischemic stroke.

This trial, now over halfway completed, focuses on patients with large vessel occlusion strokes. ARG-007 aims to protect brain cells in stroke patients by preventing cellular death post-stroke, offering hope for conditions that currently lack protective treatments.

Dallimore shared that Argenica has successfully recruited and dosed 58 patients out of a targeted 92, with expectations to complete dosing by mid-next year. “The fact that we didn’t see any serious adverse events that could have been possibly related to the drug is a massive tick of approval,” Dallimore noted, marking a significant milestone validated by the Data Safety Monitoring Board.

The broader potential for ARG-007 extends beyond stroke, addressing an estimated $18 billion market across other brain injuries, including traumatic brain injury and neurodegenerative diseases. With topline results anticipated around this time next year, the company remains optimistic about the drug's impact, especially regarding its primary safety endpoint.

For more in-depth updates on Argenica Therapeutics’ pioneering work in brain injury treatments, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and enable notifications for future insights.

#ArgenicaTherapeutics #StrokeTreatment #ARG007 #ClinicalTrials #BrainInjury #Neurology #HealthcareInnovation #DrLizDallimore #PharmaNews #Biotechnology

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews